Inventor · disambiguated record
Soumya Ray
Also filed as: RAY SOUMYA · RAY SOUMYA S
9 granted patents·24 pending applications·20 citations·filing 2006–2025
84Inventor score
Files withAVILAR THERAPEUTICS INC11MERSANA THERAPEUTICS INC4BIAL R&D INVEST S A3KOLM THERAPEUTICS INC3TRIANA BIOMEDICINES INC3
Top patents by PatentIndex Score
33 records- 0196US11819551B2ASGPR-binding compounds for the degradation of extracellular proteinsAVILAR THERAPEUTICS INC·Filed 2022·Granted Nov 21, 2023·10 cites·30 claims
- 0295US11155567B2Sting agonist compounds and methods of useMERSANA THERAPEUTICS INC·Filed 2020·Granted Oct 26, 2021·6 cites·14 claims
- 0389US12290568B2ASGPR-binding compounds for the degradation of extracellular proteinsAVILAR THERAPEUTICS INC·Filed 2024·Granted May 6, 2025·1 cites·30 claims
- 0489US12280116B2ASGPR-binding compounds for the degradation of extracellular proteinsAVILAR THERAPEUTICS INC·Filed 2024·Granted Apr 22, 2025·1 cites·30 claims
- 0588US12128106B2ASGPR-binding compounds for the degradation of extracellular proteinsAVILAR THERAPEUTICS INC·Filed 2024·Granted Oct 29, 2024·1 cites·5 claims
- 0687US11939343B2Sting agonist compounds and methods of useMERSANA THERAPEUTICS INC·Filed 2021·Granted Mar 26, 2024·1 cites·11 claims
- 0786US12312340B2Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteinsAVILAR THERAPEUTICS INC·Filed 2024·Granted May 27, 2025·0 cites·11 claims
- 0883US2025339541A1Asgpr-binding compounds for the degradation of extracellular proteinsAVILAR THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0982US12091402B2Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteinsAVILAR THERAPEUTICS INC·Filed 2023·Granted Sep 17, 2024·0 cites·29 claims
- 1081US2025213699A1Asgpr-binding compounds for the degradation of extracellular proteinsAVILAR THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1179US2025127908A1Heterobifunctional conditional inhibitorsKOLM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1279US2025129070A1Bifunctional androgen receptor compoundsKOLM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1379US2025136578A1Bifunctional androgen receptor compoundsKOLM THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1478US2025011339A1Sting agonist compounds and methods of useMERSANA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1576US2025223280A1Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteinsAVILAR THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1673US12076408B2ASGPR-binding compounds for the degradation of extracellular proteinsAVILAR THERAPEUTICS INC·Filed 2023·Granted Sep 3, 2024·0 cites·26 claims
- 1765US2024239828A1Mannose 6-phosphate or asgpr receptor binding compounds for the degradation of extracellular proteinsAVILAR THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1863US2023416245A1Adenosine analogs for the treatment of diseaseBIOINTERVENE INC·Filed 2023·Application pending·0 cites
- 1961US2024165239A1Covalent Binding Compounds for the Treatment of DiseaseHYKU BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2060US2023406854A1Covalent kras-binding compounds for therapeutic purposesUMBRA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2160US2023406853A1Covalent cdk2-binding compounds for therapeutic purposesUMBRA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2258US2024173311A1Methods and compositions for modulating fgf activityRECOVERY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2358US2024174631A1Compounds, compositions, and methods for modulating fgf activityRECOVERY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2455US2023227406A1Modulators of e3 ligasesREKINDLE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2553US2023074558A1Dimeric compounds as sting agonistsMERSANA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2652US2022380319A1Substituted benzimidazole carboxamides and their use in the treatment of medical disordersBIAL R&D INVEST S A·Filed 2020·Application pending·0 cites
- 2752US2022380314A1Substituted, saturated and unsaturated n-heterocyclic carboxamides and related compounds for their use in the treatment of medical disordersBIAL R&D INVEST S A·Filed 2020·Application pending·0 cites
- 2851US2022411388A1Substituted imidazole carboxamides and their use in the treatment of medical disordersBIAL R&D INVEST S A·Filed 2020·Application pending·0 cites
- 2951US2024425486A1Fused bicyclic substituted n-(1h-indol-7-yl)benzenesulfonamides and uses thereofTRIANA BIOMEDICINES INC·Filed 2022·Application pending·0 cites
- 3050US2024327351A1Amide and ether substituted n-(1h-indol-7-yl)benzenesulfonamides and uses thereofTRIANA BIOMEDICINES INC·Filed 2022·Application pending·0 cites
- 3150US2024190821A1Sulfonamide substituted n-(1h-indol-7-yl)benzenesulfonamides and uses thereofTRIANA BIOMEDICINES INC·Filed 2022·Application pending·0 cites
- 3249US2009233845A1Methods and compositions for non-covalently enhanced receptor bindingRAY SOUMYA·Filed 2009·Application pending·0 cites
- 3341US2006194821A1Compounds inhibiting the aggregation of superoxide dismutase-1BRIGHAM & WOMENS HOSPITAL·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Soumya Ray files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →